Innovations in Generative AI and Foundation Models

Boehringer Ingelheim and IBM will be able to employ IBM’s foundation model technology to find new candidate antibodies for the development of effective treatments

IBM has been at the forefront of creating generative AI models that extend AI’s impact beyond the domain of language

Therapeutic antibodies play a key role in the management of numerous illnesses, such as infectious, autoimmune, and cancerous conditions

Researchers from IBM and Boehringer will work together to use in-silico techniques to speed up the antibody discovery process

The defined targets are designed with antibody candidates using IBM’s foundation model technologies, which have proven effective in producing biologics and small molecules with relevant target affinities

IBM is using foundation models and Generative AI to speed up the discovery and development of new biologics and small chemicals, and this study is the latest in this endeavor